These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37880707)

  • 21. Antibody-drug conjugates: What drives their progress?
    Pander G; Uhl P; Kühl N; Haberkorn U; Anderl J; Mier W
    Drug Discov Today; 2022 Oct; 27(10):103311. PubMed ID: 35787480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
    Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.
    Püsküllüoğlu M; Rudzińska A; Pacholczak-Madej R
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188991. PubMed ID: 37758021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
    Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
    Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 Aug; 54(8):837-846. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
    Fu Z; Li S; Han S; Shi C; Zhang Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
    Barok M; Puhka M; Yazdi N; Joensuu H
    J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell killing by antibody-drug conjugates.
    Kovtun YV; Goldmacher VS
    Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
    Gerber HP; Koehn FE; Abraham RT
    Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence.
    Khosravanian MJ; Mirzaei Y; Mer AH; Keyhani-Khankahdani M; Abdinia FS; Misamogooe F; Amirkhani Z; Bagheri N; Meyfour A; Jahandideh S; Barpour N; Nikmanesh Y; Shahsavarani H; Abdollahpour-Alitappeh M
    Life Sci; 2024 Sep; 352():122910. PubMed ID: 39002610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
    Papachristos A; Pippa N; Demetzos C; Sivolapenko G
    Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
    Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
    Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug conjugate-based anticancer therapy - Current status and perspectives.
    Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
    Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.